Using C. Elegans mutants to elucidate Anthelmintic compounds’ mechanisms of action

Status
Completed
Start date
End date
Start stage
Hit ID
End stage
Hit ID
Disease
Soil-transmitted helminthiasis (STH)
Onchocerciasis
Research areas
Drug

Dr. Dent at McGill University had developed C. elegans models of STH, which included mutant strains resistant to common anti-helmint drugs. AstraZeneca and DNDi were interested in determining whether their hits from a phenotypic Onchocerca screen targeted established or novel pathways in helminths. AstraZeneca shared their hits with Dr. Dent, who screened the compounds in his C. elegans model.